42 results about "Glidant" patented technology

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The invention discloses a high-filling high-toughness PP (polypropylene) flame-retardant material and a preparation method thereof, and the high-filling high-toughness PP flame-retardant material comprises the following raw materials in percentage by weight: 45-52% of modified bamboo powder; the total proportion of the PP and the PP-g-MAH is 15%-20%, and the weight ratio of the block copolymerized PP to the PP-g-MAH is (1: 0.5)-(1: 1.5); the proportion of the POE-g-MAH is 10% to 22%; the proportion of the flame retardant is 12.5 to 14.5 percent; the proportion of the antioxidant is 0.4%-0.5%; synergistic and efficient reinforcing and toughening of the high-filling material are achieved, the small-amount and efficient result reserves enough space for increasing the proportion of the flame retardant in a blending system, and therefore high flame retardance of the material is achieved.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

A pharmaceutical composition, and a preparation method therefor and the use thereof. The pharmaceutical composition contains: (4aR,8R)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,4,4a,6,8-hexahydro-1H-pyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridin-5,7-dione or a pharmaceutically acceptable salt thereof as an active ingredient; and one or more selected from a filler, a disintegrant, a lubricant, a glidant and a binder. The pharmaceutical composition has good stability and drug dissolution, and the preparation process is simple and is suitable for industrial production.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a roxithromycin preparation and a preparation method thereof. The roxithromycin preparation is prepared from the following raw materials: roxithromycin, a stabilizer, a glidant, a filler, a binder and a lubricant. The stabilizer is a mixture of hydroxypropyl methyl cellulose and povidone. The glidant is talc. The stabilizer system used in the traditional high-pressure homogenization technology (HPH) is optimized according to the particularity of the roxithromycin raw material. The hydroxypropyl methyl cellulose and the povidone are used together, and the talc is introduced to improve the powder properties of the prepared nanocrystals, so that the subsequent production and manufacturing are facilitated. The preparation prepared according to the method has stable drug quality and accurate dosage.

The application belongs to the technical field of medicine, and particularly relates to a kind of opicapone oral disintegrating tablets and a preparation method thereof.The active component of the opicapone oral disintegrating tablet is opicapone, and the components are as follows according to weight percentage: opicapone 15-25%; filler 60-70%; glidant 1-4%; lubricant 1-4%; first disintegrating agent 2-6%; and second disintegrating agent 2-6%, wherein the first disintegrating agent and the second disintegrating agent are different, and preferably, the weight content of the opicapone is 15-20%.The opicapone oral disintegrating tablet of the application is suitable for the adjuvant therapy of levodopa / carbidopa, has a fast disintegration rate, stable product quality, does not need to be taken with water, and has strong patient compliance; in addition, the preparation process of the opicapone oral disintegrating tablet of the application is simple, has low cost, and is suitable for mass production.

The invention relates to a furosemide tablet and a preparation method thereof.The furosemide tablet is prepared from, by weight, 25.00% of furosemide, 40%-45% of filler, 27%-33% of adhesive, 0.5%-1.5% of lubricant, 1.0%-2.0% of anti-sticking agent and 0.5%-1.5% of flow agent.The furosemide tablet is prepared by adopting the technology that purified water is directly added without preparing the adhesive; a wet granulation process is adopted, the controllability of process parameters in the production process is high, the human influence of operation of multiple process steps is reduced, the quality stability of the medicine is effectively improved, the quality of the medicine is equivalent to that of a commercially available reference preparation, and multiple dissolution curves are similar to that of the reference preparation; the in-vitro dissolution behavior similar to that of a reference preparation is shown, the quality is stable, and the dissolution behaviors among batches are consistent.

The invention discloses an estradiol valerate film-coated tablet and a preparation method thereof. The estradiol valerate film-coated tablet comprises the following components in parts by weight: 1 part of estradiol valerate, 60-80 parts of a filler, 10-25 parts of a disintegrating agent, 5-12 parts of an adhesive, 1-3 parts of a flow aid, 1-3 parts of a lubricant and 8-14 parts of a film coating premix, and the filling agent is anhydrous lactose. After a sugar coating is changed into a film coating, the front end of the preparation is obviously and quickly dissolved out and is not similar to the original sugar-coated tablet, the tablet core is disintegrated in a corrosion manner by adjusting the dosage of lactose in the prescription, and the whole dissolution of the tablet is similar to the dissolution of the original sugar-coated tablet by adjusting the weight increment of the film coating. The process is simple, industrial production is facilitated, and the stability of the preparation is obviously improved.

The present application relates to a kind of upatin sustained-release tablets and preparation method thereof.The present application uses mannitol, microcrystalline cellulose as filler, hydroxypropyl methyl cellulose as matrix material, malic acid as pH regulator, colloidal silicon dioxide as glidant, magnesium stearate as lubricant, after mixing raw drug with one or more excipients, dry granulation, solve the upatin preparation in the tabletting process due to the hygroscopicity of pH regulator and cause the problem of astringent, sticky and product quality change, shorten the drying time of moisture control in coating process, tablet is more stable in the process of acceleration test and influencing factor test.

The present invention provides a pharmaceutical composition comprising ticagrelor at a dose of 90 mg, acetylsalicylic acid at a dose of from 75 to 100 mg, at least one of a diluent, a binder, a wetting agent, a glidant, and a lubricant. The pharmaceutical composition of the present invention solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. Said pharmaceutical composition is stable, such that the composition is safe and effective in the treatment and prevention of cardiovascular diseases. The invention is further directed to a process for manufacturing a pharmaceutical composition.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The invention discloses an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems of low bioavailability, large administration dosage, high side effect risk and the like of ibrutinib, the invention provides an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, the pharmaceutical composition comprises an active substance ibrutinib monolauryl sulfate, a filler, a release regulator and / or other auxiliary materials, the other auxiliary materials comprise at least one of a lubricant, a disintegrating agent and a flow aid; the preparation is a capsule or a tablet. According to the preparation of the ibrutinib monolaurinol sulfate composition prepared by adopting granulation or direct mixing, the bioavailability is greatly improved, and the dosage is greatly reduced under the condition that the blood exposure is basically unchanged; meanwhile, relatively stable blood concentration can be maintained, and the preparation has the advantages of small toxic and side effects, convenience in taking, high bioavailability and the like.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to a Pingfibrate tablet and a preparation method thereof, and aims to solve the problem that the Pingfibrate tablet is relatively slow in dissolution speed, and the Pingfibrate tablet prepared by the preparation method of the Pingfibrate tablet can improve the content uniformity of Pingfibrate and improve the bioavailability of the Pingfibrate tablet. The impurities of the palmacate tablet are reduced; the palmitate tablet comprises the following components in percentage by weight: 0.05%-0.1% of palmitate, 70%-90% of a filling agent, 1%-8% of a disintegrating agent, 1%-5% of a flow aid, 1%-5% of a lubricating agent and 2%-4% of a coating material.

This invention relates to a compustin sustained-release tablet and its preparation method. The compustin sustained-release tablet comprises a tablet core and a film coating layer covering the tablet core; the components of the compustin sustained-release tablet, by weight percentage, are 94.5%~98.3% sustained-release tablet core and 1.7%~5.5% film coating layer; the tablet core, by weight percentage, comprises the following raw material components: 32%~53% active ingredient, 30%~50% sustained-release material, 10%~30% filler, 1%~3% gliding agent, and 0.2%~1% lubricant, wherein the active ingredient is compustin; the film coating layer comprises a film-forming agent, polyethylene glycol, and additives, wherein the mass ratio of the film-forming agent, polyethylene glycol, and additives is (2~6.4):1:(1.7~5.3). Compared with the prior art, the preparation process of this invention is simple, and the obtained compustin sustained-release tablets have good release rate, stability, and bioequivalence, and are easy to industrialize.

A spray-dried solid dispersion comprising: (a) 3-[4-(4-amino-piperidin-l-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically acceptable polymer; wherein the API is dispersed in a polymer matrix formed by the pharmaceutically acceptable polymer. A tablet comprising the spray-dried solid dispersion and one or more pharmaceutically acceptable ingredients selected from one or more diluents, one or more disintegrants, one or more lubricants, one or more glidants. The tablet is for use in the treatment of acromegaly or a neuroendocrine tumor or both in a human by oral administration.

The invention discloses an imrecoxib solid preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the solid preparation comprises the following components by mass: 15-25% of imrecoxib, 10-40% of pea maltodextrin, 10-40% of Soluplus, 1-3% of poloxamer, 10-30% of a filler, 10-20% of a disintegrating agent, 0.8-1.2% of a flow aid and 0.8-1.2% of a lubricant. Through synergistic interaction of triple carriers, Soluplus inhibits drug crystallization by means of hydrogen bonds and promotes dispersion; the poloxamer reduces the surface tension and improves the dispersity and the dissolution rate; the pea maltodextrin plays an anti-oxidation role, improves the sphericity, fluidity and stability of the particles, and is low in cost. Aiming at the difficulties that imrecoxib is low in solubility, easy to oxidize and the like, medicine dissolution is remarkably improved, related substances are more stable, and both process robustness and cost control are considered.

This invention discloses a highly stable bumetanide solid dosage form comprising bumetanide, an antioxidant, a pH adjuster, a filler, a binder, a disintegrant, a surfactant, a lubricant, and a flow aid. It can solve the problem of N-nitrosobumetanide impurities and other impurities being generated during the production and storage of the dosage form, while maintaining good dissolution behavior.

The invention relates to a dextromethorphan hydrobromide quinidine sulfate capsule and a preparation method thereof. The dextromethorphan hydrobromide quinidine sulfate capsule comprises dextromethorphan hydrobromide, quinidine sulfate, a filling agent, a disintegrating agent, a flow aid, a lubricating agent and a capsule shell. The preparation process comprises the following steps: uniformly mixing the active ingredients with part of the auxiliary materials, preparing into particles through dry granulation, adding the lubricant, mixing, and filling into capsules. According to the dextromethorphan hydrobromide quinidine sulfate capsule and the preparation method thereof, the novel crystal form of quinidine sulfate found and disclosed for the first time is adopted, under the specific prescription, the stability of a preparation composition is improved and is kept consistent with the dosage form of an original research medicine, meanwhile, the dextromethorphan hydrobromide quinidine sulfate capsule provided by the invention is simple in preparation process, the quality of products between batches and in batches is stable, and the dextromethorphan hydrobromide quinidine sulfate capsule is suitable for industrial mass production.

A soft thermoplastic elastomer powder has a thermal conductivity coefficient of 0.25 to 0.45 W / mK, a Shore hardness of 20D to 49D, a process window of ≥20° C., and a melt viscosity of less than 1,000 Pa*s (0.63 rad / s) at a specific temperature (Tm+30° C.). The soft thermoplastic elastomer powder includes 100 parts by weight of a thermoplastic polyurethane elastomer, 0.01 to 2.0 parts by weight of a thermal conductive agent, and 0.05 to 2.0 parts by weight of a flow aid agent. The process window of the thermoplastic polyurethane elastomer is ≥15° C. The thermal conductivity coefficient of the thermal conductive agent is 50 to 400 W / mK, and the particle size of the thermal conductive agent is 0.5 μm to 6 μm.

The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w / w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18μm to about 22μm.

The invention discloses a diclofenac sodium sustained-release tablet and a preparation method thereof, the sustained-release tablet takes diclofenac sodium as an active ingredient, a waxy sustained-release framework material, a filler, an adhesive, a glidant, a lubricant and a coating material are supplemented, and 12-24 hours of stable release is realized by optimizing a hot melting granulation process; by expanding the selection range of auxiliary materials and simplifying the production steps, the product has good compressibility, hardness of 60-100N, friability of less than 0.6%, excellent dissolution performance, release of 25%-30% in one hour and release of more than or equal to 90% in 24 hours in a phosphate buffer solution with pH of 6.8, stability, acceleration of 6 months at 40 DEG C / 75% RH and long-term storage of 12 months at 25 DEG C / 60% RH, is consistent with in-vitro pharmaceutical characteristics of a control preparation, and is suitable for industrial production.

The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w / w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 μm to about 22 μm.

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising levetiracetam or pharmaceutically acceptable salts thereof, at least one or more disintegrant, at least one or more diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The present invention relates to a tablet composition comprises brexpiprazole or a salt thereof and at least one binder and at least one glidant, wherein glidant is colloidal silicon dioxide. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.

The application discloses an opicapone capsule, which comprises a capsule content, wherein the capsule content is prepared by mixing opicapone solid dispersion powder with pharmaceutical excipients; the opicapone solid dispersion powder is obtained by low-temperature crushing of a solid dispersion prepared by hot melt extrusion of opicapone raw material, a hydrophilic polymer carrier and a plasticizer; and the pharmaceutical excipients comprise a filler, a disintegrant, a glidant and a lubricant. In the application, the poorly soluble opicapone is highly dispersed in the hydrophilic polymer carrier in a molecular or amorphous state, the dissolution rate and degree of the drug are improved, and the bioavailability of the drug is increased.

The application discloses a compound tablet for treating hypertension, which comprises telmisartan, benzenesulfonic acid amlodipine, an alkalizing agent, a binder, a filling agent, a lubricant and a flow aid, and is characterized in that: the benzenesulfonic acid amlodipine is externally attached with a coating film; the coating material of the coating film is a gastric soluble coating material stable under an alkaline condition; and the weight ratio of the coating material to the benzenesulfonic acid amlodipine is (1-2.5): 1. The coating material is one or more of hydroxypropyl methyl cellulose, Eudragit E series and hydroxypropyl cellulose. The application provides a telmisartan amlodipine tablet with high stability and outstanding dissolution performance.

The invention discloses a sildenafil citrate orally disintegrating tablet and a preparation method thereof, and the sildenafil citrate orally disintegrating tablet comprises the following components in parts by weight: 68-75 parts of sildenafil citrate, 300-320 parts of mannitol, 15-19 parts of polyvinylpolypyrrolidone, 55-75 parts of polyvinyl acetate aqueous dispersion, 20-35 parts of a disintegrating agent, 20-35 parts of a filler, 3-6 parts of a flow aid and 2-5 parts of a coloring agent. 5-20 parts of a flavoring agent, 5-20 parts of an aromatic and 5-20 parts of a lubricant. According to the product disclosed by the invention, the dissolution rate is improved, the bitterness of the preparation is covered, the taste and smell of the product are improved, the stability of the product and the compliance of a patient are improved, and the production cost is reduced.

The invention provides a novel preparation method of an irbesartan composition, and belongs to the technical field of pharmaceutical preparations, the irbesartan composition comprises irbesartan and silicon dioxide, the irbesartan and the silicon dioxide are subjected to wet grinding in a planetary ball mill, and the mass ratio of the irbesartan to the silicon dioxide is (50: 1)-(100: 1); the particle size of irbesartan is not greater than 50 microns; the composition can also comprise one or more of a filler, a disintegrating agent, an adhesive, a lubricant and a flow aid. According to the irbesartan composition, amorphous silicon dioxide is used as a hydrophilic porous carrier to increase the specific surface area of a medicine and promote the wettability of the medicine, and irbesartan is ground into nano-scale particle size by adopting a wet grinding process and is embedded into silicon dioxide, so that the irbesartan composition is prepared. According to the irbesartan tablet, the dissolution rate and oral bioavailability of irbesartan under a low-acid condition can be remarkably improved, an organic solvent and a solubilizer do not need to be used, the medicine storage stability can be improved, the raw material cost is low, the compatibility of existing production equipment is good, and the irbesartan tablet is suitable for industrial mass production.

The invention relates to the technical field of veterinary drugs, in particular to a compound febantel tablet and a preparation method thereof. The dosage form of the compound febantel tablet is a tablet. Comprising 24.5 to 42 parts of a coating material taking febantel and praziquantel as active ingredients, 14 to 16 parts of pyrantel pamoate and 37.1 to 70.5 parts of a pharmaceutical adjuvant. The pharmaceutic adjuvants comprise a filling agent, an internal disintegrating agent, an internal flow aid, a disintegration promoting agent, an adhesive, a lubricating agent, an external disintegrating agent, an external flow aid, a coloring agent and a flavoring agent. The preparation method of the compound febantel tablet comprises the following steps: mixing the coating material, the pyrantel pamoate, the filling agent, the internal disintegrating agent, the internal flow aid, the disintegration promoting agent, the adhesive and the lubricant, granulating, drying, performing screen finishing, adding the external disintegrating agent, the external flow aid, the coloring agent and the flavoring agent, uniformly mixing, and tabletting. The tablet can be rapidly disintegrated, is stable in dissolution, is beneficial to drug release, and has a good taste.